Sam Brusco, Associate Editor01.31.24
CVRx has appointed Kevin Hykes as its new president and CEO, effective February 12. He succeeds Nadim Yared, who is retiring from the company and resigning his board seat and will consult with CVRx to smooth the transition.
Hykes has served on CVRx’s board since December 2022 and will continue to do so. He is currently the president and CEO of Augmedics, a firm focused on augmented reality surgical navigation.
Before Augmedics, he was president and CEO of Bardy Diagnostics, which was bought by Hillrom in August 2021. Prior to Bardy, he was president and CEO of Relievant Medsystems (acquired by Boston Scientific), and operating partner at Versant Ventures, chairman and CEO of Metavention, CEO of Cameron Health (acquired by Boston Scientific), and chief commercial of Visiogen (acquired by Abbott).
Before joining Visiogen, he spent 16 years at Medtronic in the company’s CRM, Neurostimulation, and Cardiac Surgery businesses.
“I am excited to be stepping into the role of CEO after over a year as an independent board member. I have spent the last 32 years commercializing disruptive medical devices like Barostim with the goal of bringing them to standard of care and making a difference in patient’s lives,” said Hykes. “The team has done a tremendous job demonstrating a strong clinical benefit and driving commercial adoption of Barostim, and has generated a significant amount of momentum up to this point. My goal is to leverage this momentum and to continue to build the organization to drive and support further commercial success.”
Hykes has served on CVRx’s board since December 2022 and will continue to do so. He is currently the president and CEO of Augmedics, a firm focused on augmented reality surgical navigation.
Before Augmedics, he was president and CEO of Bardy Diagnostics, which was bought by Hillrom in August 2021. Prior to Bardy, he was president and CEO of Relievant Medsystems (acquired by Boston Scientific), and operating partner at Versant Ventures, chairman and CEO of Metavention, CEO of Cameron Health (acquired by Boston Scientific), and chief commercial of Visiogen (acquired by Abbott).
Before joining Visiogen, he spent 16 years at Medtronic in the company’s CRM, Neurostimulation, and Cardiac Surgery businesses.
“I am excited to be stepping into the role of CEO after over a year as an independent board member. I have spent the last 32 years commercializing disruptive medical devices like Barostim with the goal of bringing them to standard of care and making a difference in patient’s lives,” said Hykes. “The team has done a tremendous job demonstrating a strong clinical benefit and driving commercial adoption of Barostim, and has generated a significant amount of momentum up to this point. My goal is to leverage this momentum and to continue to build the organization to drive and support further commercial success.”